Epstein-Barr virus vaccine - GlaxoSmithKline/MedImmune Vaccines

Drug Profile

Epstein-Barr virus vaccine - GlaxoSmithKline/MedImmune Vaccines

Alternative Names: 268664; EBV gp350 - Henogen; EBV vaccine 268664 - GlaxoSmithKline; GSK Biologicals' EBV vaccine (268664); GSK-268664; HENO 4; Recombinant gp350 vaccine for infectious mononucleosis - GlaxoSmithKline

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator MedImmune Vaccines
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Epstein-Barr virus infections; Infectious mononucleosis; Post-transplant lymphoproliferative disorder

Most Recent Events

  • 20 Apr 2011 Epstein-Barr virus vaccine is still in phase II development
  • 06 Jul 2009 Henogen has been acquired by Novasep
  • 27 May 2009 EBV vaccine is still in phase II development trials for Epstein-Barr virus infections in Belgium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top